Cytokine Response Articles & Analysis
12 news found
Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. Despite extensive research, translating findings from bench to bedside remains a challenge. Precision Cut Lung Slices (PCLS) have emerged as a versatile tool in COPD research, offering unique advantages for understanding disease mechanisms and ...
Cytokines released during infection, inflammation, and immune responses can inhibit cancer initiation and progression. ...
Armoring cell therapies with potent cytokines such as IL12 is a promising approach to treating solid tumors, but uncontrolled constitutive expression of these payloads has limited their clinical use due to toxicity. ...
The data demonstrate that, when co-cultured with BCMA-expressing cell lines, CB-011 CAR-T cells proliferate in response to antigen, secrete cytokines consistent with robust T cell activation, and kill BCMA-positive tumor cells. ...
BenevolentAI scientists then supplemented this with relevant biological context so that the network represented, at a molecular level, how SARS-CoV-2 enters and infects cells, as well as the potentially lethal inflammatory response, the so-called ‘cytokine storm’. Focusing on these aspects, the scientific team short-listed 40 drugs, finally ...
[i] Atriva specifically develops first-in-class, host-targeting small molecules that aim to inhibit viral replication and to favorably modulate the body’s immune response to treat severe respiratory diseases induced by RNA viruses. ...
“The data we continue to generate in the Phase 1 SURPASS trial shows promising responses for patients across multiple solid tumor indications. We will continue to explore more next-gen enhancements and manufacturing improvements, informed by our ongoing translational research, to deliver the best cell therapies we can for people with cancer.” Addition of AKTi during ...
In preclinical studies, the IL-15plex + eSTING payload combination delivered by STACT resulted in primary human and mouse M2 macrophage production of type I interferon, and repolarization into a novel hybrid M1/M2 phenotype capable of tumor cell phagocytosis and priming of CD8+ T-cells. Complete tumor responses were observed in metastatic, checkpoint refractory tumors (IV ...
SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year The overall response rate (ORR) per Independent Review was 34% (36% in patients with synovial sarcoma and 25% for patients with MRCLS) and the disease control rate was 85% As of the data cut-off, afami-cel has shown a favorable benefit:risk profile ...
If you would like to learn more about this novel technology register to view the company’s upcoming webinar “Studying the Response to Cytokines Using Novel In Vitro Stem Cell Platforms". About Altis Biosystems Altis Biosystems was founded to address the biopharmaceutical industry's intense need for more accurate drug screening methods using in vitro ...
A study of the effect of CDO therapy on cytokines, growth factors and perfusion was published in the International Wound Journal. The authors found significant increases in the cytokines responsible for angiogenesis, cell growth and division, and collagen deposition. ...
And then there is your immune age – the key determinant of future health and response to disease and treatment – quantified now for the first time, creating a potential paradigm shift in drug and vaccine development and medical practice. ...